Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020;382(20):1883-93. https://www.ncbi.nlm.nih.gov/pubmed/32222134
Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314(24):1547-52. https://www.ncbi.nlm.nih.gov/pubmed/3520315
Ezekowitz JA, O'Connor CM, Troughton RW, Alemayehu WG, Westerhout CM, Voors AA, et al. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. JACC Heart Fail 2020;8(11):931-9. https://www.ncbi.nlm.nih.gov/pubmed/33039447
Lang NN, Dobbin SJH, Petrie MC. Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial. Cardiovasc Res 2020;116(12):e152-e5. https://www.ncbi.nlm.nih.gov/pubmed/32980877
Sindone AP, De Pasquale C, Amerena J, Burdeniuk C, Chan A, Coats A, et al. Consensus statement on the current pharmacological prevention and management of heart failure. Med J Aust 2022;217(4):212-7. https://www.ncbi.nlm.nih.gov/pubmed/35908234
Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Jr., Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351(20):2049-57. https://www.ncbi.nlm.nih.gov/pubmed/15533851
